Tradestie Institutional Equity Comparison Engine

CLYM vs VIVS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CLYM N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs -10117.0% ยท YoY +0.0% vs -51.4%
Momentum & Technical Winner CLYM
1Y +385.9% vs -87.0% ยท 52W Pos 46% vs 5%
Options & Structure Winner CLYM
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.28
-0.22% 1D
Market Cap $546.3M
1M Return -14.63%
1Y Return +385.86%
Forward P/E N/M
Unified AI Score
50.0 / 100 HOLD
Tech 60.0 Fund 51.0 Flow 50.0 Mom 54.0
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +385.86% VIVS -86.99% Spread: +472.85 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% VIVS TTM Op. Margin: -10117.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs VIVS. Trailing 12-month operating profitability (CLYM 0.0% vs VIVS -10117.0%) and valuation multiples (CLYM N/M vs VIVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (7) vs VIVS (0)
Institutional Metric CLYM VIVS Criterion Row Winner
Market Capitalization Scale $546.3M $2.4M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -51.4% Higher Growth CLYM
Operating Margin (TTM) Profitability 0.0% -10117.0% Higher Margin CLYM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -343.1% Higher ROE CLYM
52-Week Range Position Momentum 46% ($2โ€“$18) 5% ($0โ€“$3) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 106% Vol 0.83ฮฒ ยท 480% Vol Lower Realized Risk CLYM
Unified Institutional Score Composite Signal 50.0 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs VIVS Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.